Genzyme? Kommt noch! - 500 Beiträge pro Seite

[yucca]

Biotech mit KGV von 24! Gibts das?? Klar: Genzyme! Wer nach einer Biotech-Aktie sucht, die nicht nur auf Phantasie und Erwartung gebaut ist und sogar echt Gewinne einfährt, ist bei Genzyme richtig. Mehr dazu morgen in Topstock.

=====================================
Topstock - der kostenlose Börsenbrief
http://www.topstock.de
=====================================

[milchbubi]

na ich hoffe du hast recht. da ich den börsenbrief bekomme und vor 2 wochen bei 59,50 eingestiegen bin, kann ich mich ja getrost ins bett legen

[HRDUERR]

Genzyme Molecular Oncology ist als Spin off Gesellschaft der Firma der viel interessantere Titel. Den meisten ist nur nicht bekannt, daß Genzyme die Onkologie outgesourct hat !
Die aktuellesten Entwicklungen und Produkte laufen auf absehbare Zeit alle im Onkologie-Sektor ! Der Kursverlauf von GZMO spricht hier für sich !

[HRDUERR]

Genzyme Molecular Oncology Licenses Dendritic/Cancer Cell Fusion Technology from Dana-Farber Cancer Institute
03/08 14:13

Cancer Vaccine Clinical Trial Plans Expanded

FRAMINGHAM, Mass., March 8 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) announced
today that it has exclusively licensed dendritic/cancer cell fusion technology for all therapeutic uses from Dana- Farber
Cancer Institute. This novel cancer vaccine technology was developed by Donald Kufe, M.D., professor of medicine,
and Jianlin Gong, M.D., instructor of medicine, both at the Dana-Farber Cancer Institute and Harvard Medical School.
Genzyme Molecular Oncology is currently funding a phase I breast cancer vaccine clinical trial utilizing this technology at
the Beth Israel Deaconess Medical Center, a member of the Dana-Farber/Harvard Cancer Center.

Last week, data from a German clinical study of a cancer vaccine to treat metastatic renal cancer (kidney cancer) based
on Dr. Kufe`s and Dr. Gong`s concept of dendritic/cancer cell fusion were published in Nature Medicine (volume 6,
number 3, pp. 332-336). The study, conducted by Dr. Alexander Kugler and colleagues, showed that the cancer
vaccine prompted regression of renal cancer in some patients and demonstrated little to no toxicity. Genzyme Molecular
Oncology is not a sponsor of this trial.

"We are pleased to have the exclusive commercial rights to Dr. Kufe`s promising cell fusion technology and plan to
initiate additional cancer vaccine trials using this technology," said Gail Maderis, president, Genzyme Molecular
Oncology. "The results of the German study in kidney cancer increase our confidence in the power of this
immunotherapy approach. The cell fusion technology could be applicable to a wide range of cancer indications."

Data from preclinical studies utilizing Dr. Kufe`s and Dr. Gong`s dendritic/cancer cell fusion were published in the May
1998 issue of the Proceedings of the National Academy of Sciences (volume 95, pp. 6279-6283) and in Nature
Medicine (volume 3, pp. 558-561) in 1997.

Genzyme Molecular Oncology is funding a phase I breast cancer vaccine trial using dendritic/cancer cell fusion that was
initiated in September 1999. David Avigan, M.D., clinical director of the bone marrow transplant program at Beth Israel
Deaconess Medical Center, is the principal investigator for the trial and will enroll and treat between nine and eighteen
patients with late stage metastatic breast cancer. The trial is expected to be completed in 2000.

In addition to the breast cancer trial in progress, Dr. Avigan has recently received FDA clearance to initiate a study using
the cell fusion technology in melanoma patients. Studies in kidney cancer are also being planned. Genzyme Molecular
Oncology will fund these trials through the Dana- Farber/Harvard Cancer Center.

Dendritic/cancer cell fusion combines a patient`s dendritic cells, which are powerful immune stimulators, with their tumor
cells in a laboratory procedure. Following irradiation, the fused cells are injected back into the patient to stimulate an
immune response against the patient`s cancer. This technology may incorporate the entire menu of antigens found on the
patient`s original tumor, therefore enabling the development of cancer vaccines when specific antigens are not known.

Antigens are proteins that are present in cancer cells and function as markers to prompt an immune response to those
cells. Dendritic cells are believed to be the most effective antigen presenting cells in the human immune system. Once
administered, a cancer vaccine stimulates the immune system to seek out and destroy cancer cells that display the
antigens included in the vaccine. Because cancer vaccines elicit a systemic immune response, they have the potential to
destroy cancer wherever it is found in the body.

Genzyme Molecular Oncology is developing a new generation of cancer products focusing on cancer vaccines and
angiogenesis inhibitors. It is shaping these new therapies through the integration of its genomics, gene and cell therapy,
small-molecule drug discovery, and protein therapeutic capabilities.

A division of Genzyme Corporation, Genzyme Molecular Oncology has its own common stock intended to reflect its
economic value and track its performance.

This press release contains forward-looking statements about the initiation and completion of clinical trials using the
dendritic/cancer cell fusion technology. Actual results may differ materially depending on many factors, including without
limitation the ability to successfully enroll patients in such trials, the ability to complete such trials, and the timing and
content of decisions made by the FDA and other regulatory authorities.

Genzyme`s releases are on the World Wide Web at http://www.genzyme.com. They are also available from Genzyme`s
fax-on-demand service at 1-800-436-1443 within the United States or 1-201-521-1080 outside the United States.

[milchbubi]

hier aus top-stock02. Genzyme - jetzt noch Biotech?

Wenn es in den letzten Wochen und Monaten eine Branche gab, die im
Fokus der Anleger stand und sagenhafte Gewinne beschert hat, ist das
die Biotechnologie. In Deutschland stehen Evotec (WKN: 566480) oder
Quiagen (901626) für Gewinne von einigen hundert Prozent. Trotz
rasantem Anstieg sieht Topstock nach wie vor Potenzial für diese
beiden (Standard-)werte. Doch es gibt durchaus Aktien, die noch
weitaus niedriger bewertet sind. Das amerikanische Unternehmen
Genzyme (871137) konnte im letzten halben Jahr seinen Kurs etwa
verdoppeln - für Biotech eine schlappe Vorstellung. Im Gegensatz
zu vielen Konkurrenten erzielt das in Cambridge, MA (in direkter
Nähe zum MIT) sitzende Unternehmen sogar Gewinne. Eine breite Palette
von Produkten und Dienstleistungen sorgt für eine hervorragende
Stellung am Markt und mindert die Gefahr eines jähen Absturzes.
Auch das KGV von knapp 24 bewegt sich noch in bescheidenen Sphären.
Nachdem der charttechnische Widerstand bei 60 Euro überwunden ist,
sollte einem weiteren, signifikanten Anstieg nichts mehr im Weg
stehen.

========================================